Back to Search Start Over

Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.

Authors :
Jung HA
Noh JM
Sun JM
Lee SH
Ahn JS
Ahn MJ
Pyo H
Ahn YC
Park K
Source :
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2020 Aug; Vol. 146, pp. 23-29. Date of Electronic Publication: 2020 May 31.
Publication Year :
2020

Abstract

Objectives: The PACIFIC study demonstrated the benefits of durvalumab consolidation on progression-free survival (PFS) and overall survival (OS) among patients with unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). However, in real-world practice, patients with unresectable LA-NSCLC are heterogeneous with diverse tumor burdens and clinical factors; thus, it is important to examine the effectiveness and side effects of durvalumab when used in real clinical practice.<br />Materials and Methods: We investigated the efficacy of durvalumab consolidation and the incidence of radiation pneumonitis in patients who received concurrent chemo-radiotherapy (CCRT) for unresectable LA-NSCLC in a single institute.<br />Results: Overall, 55.3 % of patients did not meet the criteria of the PACIFIC study; however, they still received consolidation durvalumab in real-world practice. Durvalumab consolidation was associated with favorable PFS in the total population as well as in the subgroup of patients who did not meet the criteria of the PACIFIC study. However, radiation pneumonitis occurred more frequently in the durvalumab group, especially within 3-6 months after CCRT. The incidence of grade 3 radiation pneumonitis was 14.3 % in the durvalumab group versus 2.5 % in the observation group.<br />Conclusions: Durvalumab consolidation was associated with favorable PFS in patients with LA-NSCLC in clinical practice. However, careful selection of candidates for durvalumab treatment and active surveillance and appropriate management for radiation pneumonitis are needed.<br />Competing Interests: Declaration of Competing Interest Keunchil Park has an advisor role in this study and received research funding from Astra Zeneca outside of this study.<br /> (Copyright © 2020. Published by Elsevier B.V.)

Details

Language :
English
ISSN :
1872-8332
Volume :
146
Database :
MEDLINE
Journal :
Lung cancer (Amsterdam, Netherlands)
Publication Type :
Academic Journal
Accession number :
32505077
Full Text :
https://doi.org/10.1016/j.lungcan.2020.05.035